The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium's position statement

Mark D Stegall, Kenneth Troy Somerville, Matthew J. Everly, Roslyn B. Mannon, A. Osama Gaber, M. Roy First, Neetu Agashivala, Vanessa Perez, Kenneth A. Newell, Randall E. Morris, Debra Sudan, Klaus Romero, Sonya Eremenco, Maria Mattera, Nicole Spear, Amy C. Porter, Inish O'Doherty

Research output: Contribution to journalArticle

Abstract

The Transplant Therapeutics Consortium (TTC) is a public-private partnership between the US Food and Drug Administration and the transplantation community including the transplantation societies and members of the biopharmaceutical industry. The TTC was formed to accelerate the process of developing new medical products for transplant patients. The initial goals of this collaboration are the following: (a) To define which aspects of the kidney transplant drug-development process have clear needs for improvement from an industry and regulatory perspective; (b) to define which of the unmet needs in the process could be positively impacted through the development of specific drug-development tools based on available data; and (c) to determine the most appropriate pathway to achieve regulatory acceptance of the proposed process-accelerating tools. The TTC has identified 2 major areas of emphasis: new biomarkers or endpoints for determining the efficacy of new therapies and new tools to assess the safety or tolerability of new therapies. This article presents the rationale and planned approach to develop new tools to assess safety and tolerability of therapies for transplant patients. We also discuss how similar efforts might support the continued development of patient-reported outcome measures in the future.

Original languageEnglish (US)
JournalAmerican Journal of Transplantation
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Immunosuppressive Agents
Transplants
Safety
Pharmaceutical Preparations
Industry
Therapeutics
Transplantation
Public-Private Sector Partnerships
United States Food and Drug Administration
Transplant Recipients
Biomarkers
Kidney

Keywords

  • clinical trial design
  • editorial/personal viewpoint
  • immunosuppressive regimens
  • kidney transplantation/nephrology
  • mathematical model
  • organ transplantation in general
  • quality of life (QoL)
  • side effects
  • translational research/science

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients : The Transplant Therapeutics Consortium's position statement. / Stegall, Mark D; Troy Somerville, Kenneth; Everly, Matthew J.; Mannon, Roslyn B.; Gaber, A. Osama; First, M. Roy; Agashivala, Neetu; Perez, Vanessa; Newell, Kenneth A.; Morris, Randall E.; Sudan, Debra; Romero, Klaus; Eremenco, Sonya; Mattera, Maria; Spear, Nicole; Porter, Amy C.; O'Doherty, Inish.

In: American Journal of Transplantation, 01.01.2019.

Research output: Contribution to journalArticle

Stegall, MD, Troy Somerville, K, Everly, MJ, Mannon, RB, Gaber, AO, First, MR, Agashivala, N, Perez, V, Newell, KA, Morris, RE, Sudan, D, Romero, K, Eremenco, S, Mattera, M, Spear, N, Porter, AC & O'Doherty, I 2019, 'The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium's position statement', American Journal of Transplantation. https://doi.org/10.1111/ajt.15214
Stegall, Mark D ; Troy Somerville, Kenneth ; Everly, Matthew J. ; Mannon, Roslyn B. ; Gaber, A. Osama ; First, M. Roy ; Agashivala, Neetu ; Perez, Vanessa ; Newell, Kenneth A. ; Morris, Randall E. ; Sudan, Debra ; Romero, Klaus ; Eremenco, Sonya ; Mattera, Maria ; Spear, Nicole ; Porter, Amy C. ; O'Doherty, Inish. / The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients : The Transplant Therapeutics Consortium's position statement. In: American Journal of Transplantation. 2019.
@article{8078aba87d944a3fae25baa13c5136b8,
title = "The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium's position statement",
abstract = "The Transplant Therapeutics Consortium (TTC) is a public-private partnership between the US Food and Drug Administration and the transplantation community including the transplantation societies and members of the biopharmaceutical industry. The TTC was formed to accelerate the process of developing new medical products for transplant patients. The initial goals of this collaboration are the following: (a) To define which aspects of the kidney transplant drug-development process have clear needs for improvement from an industry and regulatory perspective; (b) to define which of the unmet needs in the process could be positively impacted through the development of specific drug-development tools based on available data; and (c) to determine the most appropriate pathway to achieve regulatory acceptance of the proposed process-accelerating tools. The TTC has identified 2 major areas of emphasis: new biomarkers or endpoints for determining the efficacy of new therapies and new tools to assess the safety or tolerability of new therapies. This article presents the rationale and planned approach to develop new tools to assess safety and tolerability of therapies for transplant patients. We also discuss how similar efforts might support the continued development of patient-reported outcome measures in the future.",
keywords = "clinical trial design, editorial/personal viewpoint, immunosuppressive regimens, kidney transplantation/nephrology, mathematical model, organ transplantation in general, quality of life (QoL), side effects, translational research/science",
author = "Stegall, {Mark D} and {Troy Somerville}, Kenneth and Everly, {Matthew J.} and Mannon, {Roslyn B.} and Gaber, {A. Osama} and First, {M. Roy} and Neetu Agashivala and Vanessa Perez and Newell, {Kenneth A.} and Morris, {Randall E.} and Debra Sudan and Klaus Romero and Sonya Eremenco and Maria Mattera and Nicole Spear and Porter, {Amy C.} and Inish O'Doherty",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/ajt.15214",
language = "English (US)",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients

T2 - The Transplant Therapeutics Consortium's position statement

AU - Stegall, Mark D

AU - Troy Somerville, Kenneth

AU - Everly, Matthew J.

AU - Mannon, Roslyn B.

AU - Gaber, A. Osama

AU - First, M. Roy

AU - Agashivala, Neetu

AU - Perez, Vanessa

AU - Newell, Kenneth A.

AU - Morris, Randall E.

AU - Sudan, Debra

AU - Romero, Klaus

AU - Eremenco, Sonya

AU - Mattera, Maria

AU - Spear, Nicole

AU - Porter, Amy C.

AU - O'Doherty, Inish

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The Transplant Therapeutics Consortium (TTC) is a public-private partnership between the US Food and Drug Administration and the transplantation community including the transplantation societies and members of the biopharmaceutical industry. The TTC was formed to accelerate the process of developing new medical products for transplant patients. The initial goals of this collaboration are the following: (a) To define which aspects of the kidney transplant drug-development process have clear needs for improvement from an industry and regulatory perspective; (b) to define which of the unmet needs in the process could be positively impacted through the development of specific drug-development tools based on available data; and (c) to determine the most appropriate pathway to achieve regulatory acceptance of the proposed process-accelerating tools. The TTC has identified 2 major areas of emphasis: new biomarkers or endpoints for determining the efficacy of new therapies and new tools to assess the safety or tolerability of new therapies. This article presents the rationale and planned approach to develop new tools to assess safety and tolerability of therapies for transplant patients. We also discuss how similar efforts might support the continued development of patient-reported outcome measures in the future.

AB - The Transplant Therapeutics Consortium (TTC) is a public-private partnership between the US Food and Drug Administration and the transplantation community including the transplantation societies and members of the biopharmaceutical industry. The TTC was formed to accelerate the process of developing new medical products for transplant patients. The initial goals of this collaboration are the following: (a) To define which aspects of the kidney transplant drug-development process have clear needs for improvement from an industry and regulatory perspective; (b) to define which of the unmet needs in the process could be positively impacted through the development of specific drug-development tools based on available data; and (c) to determine the most appropriate pathway to achieve regulatory acceptance of the proposed process-accelerating tools. The TTC has identified 2 major areas of emphasis: new biomarkers or endpoints for determining the efficacy of new therapies and new tools to assess the safety or tolerability of new therapies. This article presents the rationale and planned approach to develop new tools to assess safety and tolerability of therapies for transplant patients. We also discuss how similar efforts might support the continued development of patient-reported outcome measures in the future.

KW - clinical trial design

KW - editorial/personal viewpoint

KW - immunosuppressive regimens

KW - kidney transplantation/nephrology

KW - mathematical model

KW - organ transplantation in general

KW - quality of life (QoL)

KW - side effects

KW - translational research/science

UR - http://www.scopus.com/inward/record.url?scp=85060634609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060634609&partnerID=8YFLogxK

U2 - 10.1111/ajt.15214

DO - 10.1111/ajt.15214

M3 - Article

C2 - 30549395

AN - SCOPUS:85060634609

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

ER -